

1 **TITLE PAGE**

2 **Title:** Atherosclerotic Cardiovascular Disease and Health-Related Quality of Life Among Adults  
3 in the United States: National Health Interview Survey 2013-2017

4 **Authors:** Kobina K. Hagan, MBChB, MPH;<sup>1</sup> Zulqarnain Javed, PhD, MBBS, MPH;<sup>1</sup> Isaac  
5 Acquah, MBChB, MPH;<sup>1</sup> Tamer Yahya, MD;<sup>2</sup> Javier Valero-Elizondo, MD, MPH;<sup>1</sup> Adnan A.  
6 Hyder, MD, MPH, PhD;<sup>3</sup> Elias Mossiolas, MD, PhD;<sup>4,5</sup> Shubham Lahan, MD;<sup>1</sup> Miguel Cainzos-  
7 Achirica, MD, MPH, PhD;<sup>1,2</sup> & Khurram Nasir, MD, MPH, MSc<sup>1,2</sup>

8 **Affiliations:**

9 <sup>1</sup> Center for Health Data Sciences and Analytics, Houston Methodist, Houston, TX, U.S.A.

10 <sup>2</sup> Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston  
11 Methodist DeBakey Heart & Vascular Center, Houston, TX, U.S.A.

12 <sup>3</sup> Center on Commercial Determinants of Health, Milken Institute School of Public Health, The  
13 George Washington University, Washington, DC, U.S.A.

14 <sup>4</sup> Department of Health Policy, London School of Economics and Political Sciences, U.K.

15 <sup>5</sup> Centre for Health Policy, Imperial College London, U.K.

16 **Running Title:** ASCVD & Health-related Quality of Life

17 **Corresponding Author:**

18 Khurram Nasir, MD, MPH, MSc.  
19 Division of Cardiovascular Prevention and Wellness, Department of Cardiology  
20 Houston Methodist DeBakey Heart & Vascular Center  
21 6550 Fannin St Suite 1801, Houston, TX 77030  
22 E-mail: [knasir@houstonmethodist.org](mailto:knasir@houstonmethodist.org). Phone: (443) 413-6350. Twitter: [@khurramn1](https://twitter.com/khurramn1)

23 **Word Count:** Abstract (249). Full text (4,958).

24 **Tables:** 2. **Figures:** 1. **Supplemental Tables:** I-IV.

25 **ABSTRACT**

26 **Background:** A brief health-related quality of life (HRQoL) tool with construct validity for  
27 atherosclerotic cardiovascular disease (ASCVD) may facilitate integration into healthcare  
28 delivery. We examined ASCVD-related changes in the Health and Activity Limitation Index  
29 (HALex), a generic HRQoL measure comprising perceived health and activity limitation.

30 **Methods:** Using data of 155,130 respondents of the National Health Interview Survey 2013-  
31 2017, we evaluated HALex scores by ASCVD (angina, heart attack, and stroke). Lower HALex  
32 scores reflected worse HRQoL and a 0.03 change was regarded as the threshold for clinical  
33 significance. Multivariable two-part models were used to assess HALex changes ( $\beta$ , 95% CI)  
34 associated with ASCVD overall and in sex, age, and race/ethnicity groups.

35 **Results:** Overall, participants with ASCVD – 6.8%, representing 15.7 million adults – had lower  
36 HALex scores (0.67) than those without ASCVD (0.87). Females, age  $\geq$  65 years, and non-  
37 Hispanic Blacks had the lowest HALex scores. Overall, ASCVD was associated with a  
38 substantial decrement in HALex (-0.10, [-0.10, -0.09]). Interactions between ASCVD and sex,  
39 and race/ethnicity were both significant ( $p < 0.001$ ). ASCVD-associated decrement in HALex  
40 was clinically greater in: females (-0.11, [-0.12, -0.10]) than in males (-0.08, [-0.09, -0.07]); and  
41 non-Hispanic Black (-0.13, [-0.15, -0.1]) than in non-Hispanic White (-0.09, [-0.10, -0.08]).  
42 Though ASCVD impact on HALex was greater in age 18-64 years (-0.09, [-0.10, -0.08]), it was  
43 not statistically different from the elderly (-0.06, [-0.07, -0.06]).

44 **Conclusions:** ASCVD was consistently associated with lower HRQoL, as measured by HALex,  
45 across major demographics. HALex presents a feasible HRQoL tool to implement in healthcare.

46 **Keywords**

47 ASCVD; atherosclerotic cardiovascular disease; quality of life; Health and Activity Limitation

48 Index; HALex

49 **Non-standard Abbreviations and Acronyms**

50	ASCVD	atherosclerotic cardiovascular disease
51	COPD	chronic obstructive pulmonary disease
52	GED	General Educational Development
53	HALex	Health and Activity Limitation Index
54	HRQoL	health-related quality of life
55	NHIS	National Health Interview Survey
56	OR	odds ratio
57	PROM	patient-reported outcome measures
58	SE	standard error

59 **FULL TEXT**

60 **INTRODUCTION**

61 Atherosclerotic cardiovascular disease (ASCVD) is associated with a high burden of debilitating  
62 symptoms and emotional stress related to decompensation and recurrent events, and invasive  
63 management. With a plenitude of life-extending treatments and a shift in healthcare quality  
64 assessment to value-based care, there is a growing call for the routine use of patient-reported  
65 outcome measures (PROMs) like health-related quality of life (HRQoL) in the clinic beyond  
66 trials (1). HRQoL not only summarizes wellbeing from a patient's perspective, but is associated  
67 with subsequent cardiovascular events, mortality, and the patterns of healthcare utilization and  
68 expenditure (2,3).

69 However, the implementation of HRQoL assessment in clinical workflow is limited by factors  
70 including the lengthy surveys in commonly used research tools such as the 36-item Short Form  
71 Survey (or its shortened version, Short Form 12) and other utility-based tools (4). On the other  
72 hand, the Health and Activity Limitation Index (HALex) is a generic HRQoL measure that  
73 combines two items – perceived health and physical functioning – into a global score for  
74 wellbeing (5). It is mathematically derived and is not subject to the variations other HRQoL tools  
75 with community rated utility scores have owing to differing measuring techniques and  
76 geographic variation (6–8). With a low administrative burden, HALex may be useful in the clinic  
77 for assessing the impact of chronic conditions including ASCVD.

78 In this cross-sectional analysis, we described the differences in HRQoL associated with the  
79 presence of ASCVD among U.S. adults using HALex. As a convenient and reliable alternative to

80 more detailed tools, we expected ASCVD-related decrements in HALex in the total population  
81 and within sex, age, and race/ethnicity groups.

## 82 **METHODS**

### 83 **Study design and sampling**

84 This study used the 2013-2017 National Health Interview Survey (NHIS) data. The NHIS is an  
85 annual household interview survey of the United States (U.S.) civilian, non-institutionalized  
86 population sponsored by the National Center for Health Statistics and under the auspices of the  
87 Centers for Disease Control and Prevention (9). Interviews are conducted using a complex,  
88 multistage probability design to reflect changes in the distribution of the U.S. population and  
89 produce nationally representative estimates. The NHIS has four core components – Household  
90 Composition, Family, Sample Child, and the Sample Adult – which provide information on  
91 respondents' sociodemographic characteristics, health status and activity limitations, behavior  
92 indicators, and health care access and utilization. In addition, NHIS data are supplemented with  
93 survey weights to account for selection probabilities and non-response. Since NHIS data files are  
94 publicly available and de-identified, this study was exempt from Institutional Review Board  
95 review.

96 We used respondents aged  $\geq 18$  years from the Family Core, Sample Adult Core, and Person files  
97 merged and pooled over five years (2013-2017). Since NHIS data files are publicly available and  
98 de-identified, this study was exempt from the purview of Houston Methodist's Institutional  
99 Review Board.

## 100 **Study variables**

### 101 *Atherosclerotic Cardiovascular Disease*

102 Respondents who affirmed ever receiving a clinician diagnosis of “angina pectoris”, “heart  
103 attack (or myocardial infarction)”, “coronary heart disease”, or “stroke” were classified as having  
104 ASCVD. Respondents with no information on their ASCVD status (1,052 [0.7%]) were excluded  
105 from the analysis. All other NHIS participants included in the analysis were considered to not  
106 have ASCVD.

### 107 *The Health and Activity Limitation Index*

108 HALex is based on two routinely assessed health indicators included in the NHIS: perceived  
109 health status and levels of physical activity limitation (5). Responses to perceived health status  
110 are subjective and include “excellent”, “very good”, “good”, “fair”, and “poor”. The assessment  
111 of physical activity limitation is objective and the responses include: 1) not limited, 2) limited in  
112 other activities, 3) limited in major activity, 4) unable to perform a major activity, 5) unable to  
113 perform instrumental activities of daily living, and 6) unable to perform activities of daily living  
114 (personal care needs). The mathematical derivation of HALex has been described extensively  
115 (10). In brief, responses to the two items are combined in a matrix of 30 health states  
116 (**Appendix**). For persons alive, HALex scores range from 0.10 to 1.00 (11).

117 Two outcomes were assessed – our primary outcome, mean HALex score, and a secondary  
118 binary outcome, poor HALex performance. We categorized patients with HALex scores less than  
119 0.84 (i.e., 20<sup>th</sup> percentile of the study sample distribution) as having poor HALex (12). There are  
120 no widely established cut-off values for HALex, but the threshold for a clinically relevant impact

121 is suggested to be 0.03 (13). We interpreted our results with this threshold. In sum, data of  
122 155,130 participants with complete information on ASCVD and HALex, and non-zero HALex  
123 scores (i.e., alive) were used in this study.

#### 124 **Covariates**

125 Other variables included in this study were age (linear) and age group (18-64 years and  $\geq 65$   
126 years); sex (male and female); race/ethnicity (non-Hispanic White, non-Hispanic Black,  
127 Hispanic, non-Hispanic Asian, Hispanic, and Other); educational attainment (no high school  
128 diploma, high school diploma/GED equivalent, some college, and  $\geq$  college degree); health  
129 insurance plan (uninsured, any private plan, Medicare, Medicaid, and other plans); household  
130 income; obesity (body mass index  $\geq 30$  kg/m<sup>2</sup>); psychological distress within 30 days before the  
131 survey; and comorbidities, which were all self-reported. Household income categories were  
132 based on the percentage of family income relative to the federal poverty limit from the U.S.  
133 Census Bureau – high income ( $\geq 400\%$ ), middle income (200% to  $< 400\%$ ), and low income ( $<$   
134 200%). Psychological distress was ascertained with the Kessler-6 Distress Scale score<sub>(14)</sub>. For  
135 comorbidities, respondents were asked if they had ever received a clinician diagnosis of arthritis,  
136 cancer, chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, or  
137 failing/weak kidneys.

#### 138 **Statistical analysis**

139 All statistical analyses incorporated the complex survey design and weighting for selection  
140 probabilities and non-response. Variance estimation for the entire pooled cohort was obtained  
141 from the Integrated Public Use Microdata Series (<https://www.nhis.ipums.org>) (15). We assessed



142 the statistical significance of our estimates with a two-tailed alpha significance level of 5%. We  
143 used Stata version 16 software (StataCorp, College Station, Texas) for all analyses.

144 We summarized the distribution of individual characteristics – mean (SD) for age; median (IQR)  
145 for Kessler 6 score; sample frequency with weighted proportion for discrete variables) in the  
146 total population and by ASCVD status. Chi-squared, t-test, and Mann-Whitney u test statistics  
147 were used to compare the descriptive statistics between the ASCVD groups for discrete  
148 variables, linear age, and Kessler 6 score, respectively. For HALex, we provided age-and-sex  
149 adjusted least-square mean scores (with SE) for the total population and by ASCVD status.

150 For our primary multivariable analysis, we evaluated the associations between ASCVD and  
151 HALex scores using two-part models (16). All models used accounted for linear age, sex,  
152 race/ethnicity, insurance status, household income level, educational attainment, obesity, Kessler  
153 6 score, and the individual comorbidities. For the two-part modeling of HALex scores, we first  
154 performed a simple negative linear transformation ( $X = 1 - U$ , where  $U = \text{HALex}$ ) to move the  
155 utility index to a “health-utility decrement” scale with right skewness (16). Next, we fitted a  
156 first-part logit model for the likelihood of positive (vs. zero) scores, and an ordinary least squares  
157 regression in the second part for the predicted score conditioned on having a positive score. The  
158 same set of covariates were used in both models. Finally, a simple reconversion of the estimates  
159 and 95% confidence limits ( $U = 1 - X$ ) was performed to obtain results on the original HALex  
160 scale (16). About 86% of participants had complete data on all variables of interest and the  
161 highest missingness was 7.5% for household income levels with missingness for other variables  
162 ranging from 0.8 to 3.3%. Consequently, we did not impute values for any missing data.

163 In subgroup analyses by age group (18-64 years and  $\geq 65$  years), sex, and race/ethnicity, we  
164 repeated the fully adjusted analysis of HALex scores and tested for potential interactions  
165 between these characteristics and ASCVD status separately.

166 In a secondary analysis of poor HALex, we used odds ratios (OR, 95% CI) to assess the  
167 association between ASCVD and poor HALex in the overall population and in subgroups  
168 defined by age, sex, and race/ethnicity.

169

## 170 **RESULTS**

171 In our sample of 155,130 NHIS participants with complete HALex data, the estimated  
172 prevalence of ASCVD was 6.8%, representing about 15.7 million adults annually (**Table 1**).

173 Individuals with ASCVD were more likely to be men, older, have Medicare insurance plan, and  
174 reside in low-income households. They also reported a greater burden of comorbidities.

### 175 *Summary of HALex scores*

176 Overall, adults with ASCVD had lower mean HALex scores (0.67 [SE 0.01]) than those without  
177 ASCVD (0.87 [SE 0.00]). This trend was observed across all study characteristics (**Table 2**).

178 With ASCVD, females averaged a significantly lower HALex score than males (0.62 vs. 0.69), a  
179 contrast to the similar scores observed in the absence of ASCVD. With ASCVD, persons aged

180 18-64 years averaged a lower HALex score than those aged  $\geq 65$  years. The reverse – higher  
181 HALex scores among persons 18-64 years of age – was observed in the absence of ASCVD.

182 Non-Hispanic Blacks averaged the lowest HALex scores, irrespective of ASCVD status. Lower  
183 educational status, lower household income and higher psychological distress were all associated

184 with significantly lower HALex scores than the respective counterparts in both ASCVD groups.  
185 Of the comorbidities, COPD and kidney failure were associated with the lowest HALex scores  
186 reflecting their debilitating nature.

#### 187 *Multivariable ASCVD-HALex score analysis*

188 We present our multivariable analysis of HALex scores. Overall, ASCVD was associated with a  
189 clinically relevant decrease in HALex performance ( $\beta = -0.10$ ; 95% CI [-0.10, -0.09]) (**Figure 1**).  
190 We observed, in separate models, significant interactions between ASCVD and sex ( $p < 0.001$ ),  
191 and race/ethnicity ( $p < 0.001$ ). The decrement in HALex scores associated with ASCVD was  
192 greater in females ( $\beta = -0.11$ , 95% CI [-0.12, -0.10]) than in males ( $\beta = -0.08$ , 95% CI [-0.09, -  
193 0.07]). For age groups, the negative impact of ASCVD on HALex scores was observed to be  
194 greater in the younger age group ( $\beta = -0.09$ , 95% CI [-0.10, -0.08]) than those aged  $\geq 65$  years ( $\beta$   
195 = -0.06, 95% CI [-0.07, -0.06]). For racial/ethnic subgroups, the greatest ASCVD impact was  
196 observed with non-Hispanic Blacks ( $\beta = -0.13$ , 95% CI [-0.15, -0.11]). The decrement in HALex  
197 associated with ASCVD was not clinically different between non-Hispanic White ( $\beta = -0.09$ ,  
198 95% CI [-0.10, -0.08]) and Hispanics ( $\beta = -0.10$ , 95% CI [-0.12, -0.08]) groups.

#### 199 *Secondary analysis of poor HALex*

200 Overall, 17.7% (95% CI [17.4, 18.1]) of the study population performed poorly on HALex. A  
201 significantly greater proportion in the ASCVD group had poor HALex than those without  
202 ASCVD (40.3% v. 15.3%;  $p < 0.001$ ; **Appendix**). The distribution of poor HALex performance  
203 across study variables for the ASCVD groups are presented as well in the Appendix.

204 From the multivariable analysis, ASCVD was associated with increased odds of poor HALex 2.5  
205 times that observed with the group without ASCVD (OR = 2.46, 95% CI [2.28, 2.66]).  
206 Interactions between ASCVD and age group and ASCVD and race/ethnicity were statistically  
207 significant ( $p < 0.001$ ), but there was no significant interaction observed between ASCVD and  
208 sex ( $p = 0.05$ ). The increment in odds of poor HALex associated with ASCVD was higher in age  
209 18-64 years (OR = 2.84; 95% CI [2.52, 3.20]) than in age  $\geq 65$  years. Similarly, the increment in  
210 odds of poor HALex associated with ASCVD was highest in the non-Hispanic Black group (OR  
211 = 2.33; 95% CI [2.74, 4.04]). Hispanic and non-Hispanic White groups had similar increments in  
212 odds of poor HALex associated with ASCVD presence.

213

## 214 **DISCUSSION**

215 In a large survey of adults in the U.S., reporting any ASCVD condition was associated with a  
216 significantly lower HRQoL (as measured with HALex). This clinically significant difference was  
217 independent of demography, education, insurance, household income, and comorbidity burden.  
218 Further, the impact of ASCVD on lower HALex scores was significantly greater in females,  
219 adults 18-64 years of age, and non-Hispanic Black adults. The impacts of ASCVD on HALex  
220 scores and poor HALex performance were similar in the Hispanic and non-Hispanic White  
221 groups. We did not intend to establish clinical values of HALex for persons with ASCVD.  
222 Rather, we set out to corroborate the construct validity of a HRQoL tool that could be  
223 implemented in the clinical workflow without much challenge.

224 The sex differences in the impact of ASCVD on HALex is congruent with the established trend  
225 that women have poorer health outcomes in conditions like coronary heart disease (17). Women

226 may present as a diagnostic dilemma in the clinic due to confounding atypical presentations or  
227 less common pathophysiological processes. Consequently, they are less likely to receive prompt  
228 and/or appropriate management to realize optimal outcomes (18,19).

229 We also observed worse HRQoL and the largest ASCVD decrement in non-Hispanic Black  
230 compared to the other groups. A similar trend was previously observed in a national survey of  
231 adults 35-89 years of age which assessed HRQoL with various indices (20). Interestingly, the  
232 impact of ASCVD on HRQoL in Hispanic was comparable to non-Hispanic White, despite the  
233 former averaging lower HALex in the presence of ASCVD. This paradox, commonly observed  
234 in population studies on other health outcomes (21), could be related to a more resilient  
235 subjective construct of health in the face of health challenges owing to cultural values and  
236 supportive social relationships among Hispanics (22).

237 On average, we observed lower HALex scores in those 18-64 years of age with ASCVD than  
238 their older counterparts. Though not statistically significant, we also observed a greater  
239 decrement in HALex with ASCVD in the group 18-64 years of age (-0.09 vs -0.06). While  
240 younger age is associated with better health and a greater chance of recovering from ASCVD  
241 and its management, younger individuals are more likely to have maladaptive and adverse  
242 psychological experiences after their diagnosis (23). Another potential explanation to this  
243 observation is the phenomenon that aging populations may report better subjective health due to  
244 lowered expectations rather than ‘actual’ better health (24).

#### 245 *Implications*

246 The adoption into clinical workflow of a HRQoL tool like HALex – which is easy to administer  
247 and has construct validity – would be in line with the call to routinely assess PROMs in the

248 clinic. HALex is impacted by the burden of chronic disease, more so than other preference-based  
249 measures (25,26). This is in part due to the ability of the constituent perceived-health-status item  
250 to discriminate well among levels of functioning (27). As physical functioning is strongly  
251 associated with cardiovascular disease prognosis, HALex assessment could be relevant in patient  
252 management, especially in the holistic evaluation of rehabilitation (28).

253 Additionally, HALex may have utility in longitudinally assessing the impact of treatment on  
254 HRQoL (29). Under a chronic care model with self-management support strategy, patients are  
255 reinforced to assume an active and shared responsibility of their health with providers. They are  
256 educated to better recognize their health issues, acknowledge the need for health behavior  
257 modifications, and initiate and maintain such modifications. In utilizing this context of care,  
258 perceived health status (and HALex) would be based on a more comprehensive  
259 conceptualization of health standards set and evaluated by patients themselves. Consequently, for  
260 patients who may not have a change in physical functioning, a change in their valuation of their  
261 own health could signal deficiencies in care standards.

## 262 *Limitations*

263 HALex as a HRQoL measure is not without limitations. Firstly, domains of health such as  
264 emotional, mental, and social functioning, which are relevant in HRQoL (30), are omitted in  
265 HALex derivation. This may its discrimination ability, especially for populations with clustering  
266 at the highest level of health (5). Nevertheless, we accounted for psychological distress using a  
267 valid and reliable tool in the Kessler 6 distress scale, which minimizes the bias from this health  
268 domain on our estimates.

269 Secondly, the reliance of HALex on a subjectively perceived health status raises the question of  
270 how much of the difference in HALex scores may be related to differential perception. Although  
271 perceived health status tends to be congruous with objective measures of health, differences exist  
272 between the two health assessments owing to varying health expectations (or preoccupations),  
273 and the relevance of physical function to major lifetime occupation (31). Nevertheless, it is well  
274 known that the manner in which people account for the many dimensions of health when rating  
275 their overall health is relatively stable across disease populations.

276 Finally, while the NHIS is designed to be representative of the US population, the reliance on  
277 self-reports for health information including medical conditions and anthropometric  
278 measurements (i.e., weight and height) implies some potential for misclassification of study  
279 variables. However, previous studies have found a high correlation between the self-reported  
280 information in NHIS and the verified information found in other national datasets (32).

281

## 282 **CONCLUSION**

283 In conclusion, ASCVD is associated with lower HALex and this association was observed to be  
284 greater in female adults, younger age group, and non-Hispanic Black persons. HALex retains a  
285 construct validity and has a low administration burden, making it a potentially useful HRQoL  
286 tool to implement in healthcare delivery.

287 **REFERENCES**

- 288 1. Kornowski R. Patient-reported outcome measures in cardiovascular disease. *Eur Heart J -*  
289 *Qual Care Clin Outcomes* [Internet]. 2021 Aug 9 [cited 2021 Nov 16];(qcab051). Available  
290 from: <https://doi.org/10.1093/ehjqcco/qcab051>
- 291 2. Reuben DB, Tinetti ME. Goal-Oriented Patient Care — An Alternative Health Outcomes  
292 Paradigm. *N Engl J Med*. 2012 Mar 1;366(9):777–9.
- 293 3. Hostetter M, Klein S. Using Patient-Reported Outcomes to Improve Health Care Quality  
294 [Internet]. The Commonwealth Fund. [cited 2021 Nov 16]. Available from:  
295 [https://www.commonwealthfund.org/publications/newsletter-article/using-patient-reported-](https://www.commonwealthfund.org/publications/newsletter-article/using-patient-reported-outcomes-improve-health-care-quality)  
296 [outcomes-improve-health-care-quality](https://www.commonwealthfund.org/publications/newsletter-article/using-patient-reported-outcomes-improve-health-care-quality)
- 297 4. Blumenthal DM, Strom JB, Valsdottir LR, Howard SE, Wagle NW, Ho KKL, et al. Patient-  
298 Reported Outcomes in Cardiology. *Circ Cardiovasc Qual Outcomes*. 2018  
299 Nov;11(11):e004794.
- 300 5. Erickson P. Evaluation of a population-based measure of quality of life: the Health and  
301 Activity Limitation Index (HALex). *Qual Life Res Int J Qual Life Asp Treat Care Rehabil*.  
302 1998 Feb;7(2):101–14.
- 303 6. Hammerschmidt T, Zeitler HP, Gulich M, Leidl R. A comparison of different strategies to  
304 collect standard gamble utilities. *Med Decis Mak Int J Soc Med Decis Mak*. 2004  
305 Oct;24(5):493–503.
- 306 7. Lam CLK, Brazier J, McGhee SM. Valuation of the SF-6D Health States Is Feasible,  
307 Acceptable, Reliable, and Valid in a Chinese Population. *Value Health J Int Soc*  
308 *Pharmacoeconomics Outcomes Res*. 2008 Apr;11(2):295–303.
- 309 8. Abellán Perpiñán JM, Sánchez Martínez FI, Martínez Pérez JE, Méndez I. Lowering the  
310 ‘Floor’ of the Sf-6d Scoring Algorithm Using a Lottery Equivalent Method. *Health Econ*.  
311 2012;21(11):1271–85.
- 312 9. National Center for Health Statistics. NHIS - Data, Questionnaires and Related  
313 Documentation [Internet]. Centers for Disease Control and Prevention. 2021 [cited 2021 Nov  
314 17]. Available from: <https://www.cdc.gov/nchs/nhis/data-questionnaires-documentation.htm>
- 315 10. Livingston EH, Ko CY. Use of the Health and Activities Limitation Index as a Measure of  
316 Quality of Life in Obesity. *Obes Res*. 2002;10(8):824–32.
- 317 11. Asada Y. Assessment of the health of Americans: the average health-related quality of life  
318 and its inequality across individuals and groups. *Popul Health Metr*. 2005 Jul 13;3(1):7.
- 319 12. Kachan D, Fleming LE, Christ S, Muennig P, Prado G, Tannenbaum SL, et al. Health Status  
320 of Older US Workers and Nonworkers, National Health Interview Survey, 1997-2011. *Prev*  
321 *Chronic Dis*. 2015 Sep 24;12:E162.



- 322 13. Mouelhi Y, Jouve E, Castelli C, Gentile S. How is the minimal clinically important  
323 difference established in health-related quality of life instruments? Review of anchors and  
324 methods. *Health Qual Life Outcomes*. 2020 May 12;18(1):136.
- 325 14. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SLT, et al. Short  
326 screening scales to monitor population prevalences and trends in non-specific psychological  
327 distress. *Psychol Med*. 2002 Aug;32(6):959–76.
- 328 15. Blewett LA, Drew JAR, King ML, Williams KCW. IPUMS Health Surveys: National Health  
329 Interview Survey, Version 6.4 [dataset] [Internet]. Minneapolis, MN; 2019. Available from:  
330 <https://doi.org/10.18128/D070.V6.4>
- 331 16. Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating  
332 Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research  
333 Practices Task Force Report. *Value Health*. 2016 Sep 1;19(6):704–19.
- 334 17. Gao Z, Chen Z, Sun A, Deng X. Gender differences in cardiovascular disease. *Med Nov*  
335 *Technol Devices*. 2019 Dec 1;4:100025.
- 336 18. Gelber A, Drescher M, Shiber S. Sex Differences in Identifying Chest Pain as Being of  
337 Cardiac Origin Using the HEART Pathway in the Emergency Department. *J Womens Health*  
338 2002. 2022 Jul;31(7):926–31.
- 339 19. Zhao M, Woodward M, Vaartjes I, Millett ERC, Klipstein Grobusch K, Hyun K, et al. Sex  
340 Differences in Cardiovascular Medication Prescription in Primary Care: A Systematic  
341 Review and Meta-Analysis. *J Am Heart Assoc*. 2020 Jun 2;9(11):e014742.
- 342 20. Pereira CCA, Palta M, Mullahy J, Fryback DG. Race and preference-based health-related  
343 quality of life measures in the United States. *Qual Life Res Int J Qual Life Asp Treat Care*  
344 *Rehabil*. 2011 Aug;20(6):969–78.
- 345 21. Ruiz JM, Steffen P, Smith TB. Hispanic Mortality Paradox: A Systematic Review and Meta-  
346 Analysis of the Longitudinal Literature. *Am J Public Health*. 2013 Mar;103(3):e52–60.
- 347 22. Gallo LC, Penedo FJ, Espinosa de los Monteros K, Arguelles W. Resiliency in the Face of  
348 Disadvantage: Do Hispanic Cultural Characteristics Protect Health Outcomes? *J Pers*.  
349 2009;77(6):1707–46.
- 350 23. Okunrintemi V, Benson EMA, Derbal O, Miedema MD, Blumenthal RS, Tibuakuu M, et al.  
351 Age-specific differences in patient reported outcomes among adults with atherosclerotic  
352 cardiovascular disease: Medical expenditure panel survey 2006–2015. *Am J Prev Cardiol*.  
353 2020 Sep 1;3:100083.
- 354 24. Sarkisian CA, Prohaska TR, Wong MD, Hirsch S, Mangione CM. The relationship between  
355 expectations for aging and physical activity among older adults. *J Gen Intern Med*. 2005  
356 Oct;20(10):911–5.

- 357 25. Hanmer J, Cherepanov D, Palta M, Kaplan RM, Feeny D, Fryback DG. Health Condition  
358 Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by  
359 Preference-Based Health Index. *Med Decis Mak Int J Soc Med Decis Mak*. 2016  
360 Feb;36(2):264–74.
- 361 26. Stewart ST, Cutler DM, Rosen AB. Comparison of trends in US health-related quality of life  
362 over the 2000s using the SF-6D, HALex, EQ-5D, and EQ-5D visual analog scale versus a  
363 broader set of symptoms and impairments. *Med Care*. 2014 Dec;52(12):1010–6.
- 364 27. Idler EL, Kasl SV. Self-ratings of health: do they also predict change in functional ability? *J*  
365 *Gerontol B Psychol Sci Soc Sci*. 1995 Nov;50(6):S344-353.
- 366 28. Shepherd CW, While AE. Cardiac rehabilitation and quality of life: a systematic review. *Int*  
367 *J Nurs Stud*. 2012 Jun;49(6):755–71.
- 368 29. Health Services Delivery Programme, Division of Health Systems and Public Health.  
369 Integrated care models: an overview [Internet]. World Health Organization: Regional Office  
370 for Europe; 2016 Oct p. 1–31. Available from:  
371 [https://www.euro.who.int/\\_\\_data/assets/pdf\\_file/0005/322475/Integrated-care-models-](https://www.euro.who.int/__data/assets/pdf_file/0005/322475/Integrated-care-models-overview.pdf)  
372 [overview.pdf](https://www.euro.who.int/__data/assets/pdf_file/0005/322475/Integrated-care-models-overview.pdf)
- 373 30. McDowell I. *Measuring Health: A guide to rating scales and questionnaires* [Internet]. 3rd  
374 ed. New York: Oxford University Press; 2006 [cited 2021 Nov 18]. 764 p. Available from:  
375 [https://oxford.universitypressscholarship.com/10.1093/acprof:oso/9780195165678.001.0001/](https://oxford.universitypressscholarship.com/10.1093/acprof:oso/9780195165678.001.0001/acprof-9780195165678)  
376 [acprof-9780195165678](https://oxford.universitypressscholarship.com/10.1093/acprof:oso/9780195165678.001.0001/acprof-9780195165678)
- 377 31. Maddox GL. Some Correlates of Differences in Self-assessment of Health Status Among the  
378 Elderly1. *J Gerontol*. 1962 Apr 1;17(2):180–5.
- 379 32. Nelson DE, Powell-Griner E, Town M, Kovar MG. A Comparison of National Estimates  
380 From the National Health Interview Survey and the Behavioral Risk Factor Surveillance  
381 System. *Am J Public Health*. 2003 Aug;93(8):1335–41.

382 **FIGURE LEGENDS**

383 Figure 1. Association between HALex and ASCVD from the National Health Interview Survey  
384 2013-2017.

385 [Caption] <sup>1</sup> Adjusted for sex, age (linear), race/ethnicity, insurance status, household income  
386 level, educational attainment, obesity, Kessler-6 score, and comorbidities.

387 <sup>2</sup> Adjusted for age (linear), race/ethnicity, insurance status, household income level, educational  
388 attainment, obesity, Kessler-6 score, and comorbidities.

389 <sup>3</sup> Adjusted for sex, race/ethnicity, insurance status, household income level, educational  
390 attainment, obesity, Kessler-6 score, and comorbidities.

391 <sup>4</sup> Adjusted for sex, age (linear), insurance status, household income level, educational attainment,  
392 obesity, psychological distress, and comorbidities.

393 \* *Other* race/ethnicity group not shown due to limited sample size.

394 † p-value for the test of interaction with Bonferroni correction.

395 ‡ Statistically significant.

396 **DECLARATIONS**

397 **Ethics approval and consent to participate**

398 Not applicable.

399 **Consent for publication**

400 Not applicable.

401 **Availability of data and materials**

402 The datasets analyzed in the current study are available from the corresponding author on  
403 reasonable request.

404 **Competing interests**

405 **K.N.** is on the advisory board of Amgen and Novartis, and his research is partly supported by the  
406 Jerold B. Katz Academy of Translational Research. **K.N.** and **M.CA.** are on the Steering  
407 Committee of the PAK-SEHAT Study, partially funded by an unrestricted research grant from  
408 Getz Pharma. **A.A.H.** declares current funding from the United States National Institutes of  
409 Health, the World Bank, and the World Health Organization. The other authors report no  
410 conflicts of interest relevant to this work.

411 **Funding**

412 Not applicable

413 **Authors' contributions**

414 K.K.H., K.N., and Z.J. contributed to the study's conception and design. Material preparation and  
415 data analysis were performed by K.K.H. and J.VE. The first draft of the manuscript was prepared  
416 by K.K.H. and Z.J. S.L. prepared all figures. All authors reviewed the manuscript. All authors  
417 read and approved the final manuscript.

418 **Acknowledgements**

419 Not applicable.

Table 1. Characteristics of adults  $\geq 18$  years from the National Health Interview Survey (2013-2017).

Characteristic	Total	No ASCVD	ASCVD
Sample	N=155,130	142,866	12,264
Weighted population, n (%)	231,560,617	215,812,388 (93.2)	15,748,229 (6.8)
Sociodemographic			
Sex*			
Male	73,825 (48.3)	65,607 (47.7)	8,218 (56.9)
Female	90,525 (51.7)	82,985 (52.3)	7,540 (43.1)
Mean age*	49.75 (SD 18.39)	48.04 (SD 17.93)	66.84 (SD 13.63)
Age group*			
18-64 years	121,956 (78.62)	116,295 (81.40)	5,661 (46.16)
$\geq 65$ years	33,174 (21.38)	26,571 (18.60)	6,603 (53.84)
Race/Ethnicity*			
Non-Hispanic White	100,223 (65.2)	91,521 (64.6)	8,702 (72.8)
Non-Hispanic Black	20,284 (12.1)	18,492 (12.1)	1,792 (12.5)
Non-Hispanic Asian	8,880 (5.9)	8,523 (6.1)	357 (3.2)
Hispanic	23,759 (15.8)	22,529 (16.3)	1,230 (10.3)
Other	1,984 (1.0)	1,801 (1.0)	183 (1.2)
Insurance status*			
Uninsured	18,953 (12.3)	18,277 (12.8)	676 (6.1)
Private	78,944 (56.9)	76,628 (59.3)	2,316 (23.7)
Medicare	29,864 (115.5)	24,124 (13.4)	5,740 (45.2)
Medicaid	17,930 (11.0)	15,513 (10.5)	2,417 (17.7)
Other	7,611 (4.3)	6,613 (4.1)	998 (7.4)
Family income*			
High income	51,472 (40.5)	48,691 (41.3)	2,781 (29.8)
Middle income	40,789 (28.7)	37,619 (28.6)	3,170 (29.9)
Low income	51,546 (30.8)	46,261 (30.1)	5,285 (40.3)
Education*			
$\geq$ College degree	65,124 (42.9)	61,444 (43.8)	3,680 (32.5)
Some college	30,612 (19.7)	28,374 (19.8)	2,238 (18.0)
High school/GED	38,533 (25.0)	34,867 (24.6)	3,666 (30.1)
< High school	20,251 (12.4)	17,648 (11.9)	2,603 (19.4)
Clinical characteristics			
Median Kessler 6 score* (psychological stress)	1 (0-4)	1 (0-4)	2 (0-6)
Arthritis*	37,510 (21.5)	31,133 (19.4)	6,377 (50.0)
Cancer*	14,195 (8.1)	11,618 (7.2)	2,577 (20.4)

COPD*	5,156 (2.7)	3,327 (1.9)	1,829 (13.6)
Diabetes*	14,910 (8.8)	11,353 (7.3)	3,557 (29.6)
Failing/weak kidneys*	3,172 (1.7)	2,052 (1.2)	1,120 (8.6)
Obesity*	49,863 (31.9)	45,059 (31.3)	4,804 (40.1)
Hypertension*	49,960 (29.1)	40,998 (26.0)	8,962 (71.7)
Column % weighted to the US population presented.			
* All tests of comparison by ASCVD status were statistically significant ( $p < 0.001$ ).			
Abbreviations: ASCVD – atherosclerotic cardiovascular disease. COPD – chronic obstructive pulmonary disease. GED – general educational development.			

Table 2. Age- and sex-adjusted mean HALex scores of adults  $\geq 18$  years from the National Health Interview Survey (2013-2017).

Characteristics	Total	ASCVD	No ASCVD
Overall	0.85 (0.00)	0.67 (0.01)	0.87 (0.00)
<b>Sociodemographic</b>			
Sex			
Male	0.86 (0.00)	0.69 (0.00)	0.87 (0.00)
Female	0.84 (0.00)	0.62 (0.01)	0.86 (0.00)
Age group			
18-64 years	0.85 (0.00)	0.61 (0.01)	0.87 (0.00)
$\geq 65$ years	0.81 (0.00)	0.64 (0.01)	0.82 (0.00)
Race/ethnicity			
Non-Hispanic White	0.86 (0.00)	0.68 (0.01)	0.87 (0.00)
Non-Hispanic Black	0.81 (0.00)	0.58 (0.01)	0.83 (0.00)
Non-Hispanic Asian	0.87 (0.00)	0.71 (0.02)	0.89 (0.00)
Hispanic	0.83 (0.00)	0.63 (0.01)	0.85 (0.02)
Other	0.78 (0.01)	0.60 (0.03)	0.80 (0.01)
Insurance status			
Uninsured	0.82 (0.00)	0.66 (0.01)	0.84 (0.00)
Private	0.89 (0.00)	0.77 (0.01)	0.90 (0.00)
Medicare	0.67 (0.00)	0.51 (0.00)	0.68 (0.00)
Medicaid	0.68 (0.00)	0.49 (0.01)	0.70 (0.00)
Other	0.81 (0.00)	0.65 (0.01)	0.83 (0.00)
Education			
$\geq$ College degree	0.89 (0.00)	0.73 (0.01)	0.90 (0.00)
Some college	0.84 (0.00)	0.67 (0.01)	0.86 (0.00)
High school/GED	0.82 (0.00)	0.64 (0.01)	0.84 (0.00)
$<$ High school	0.77 (0.00)	0.58 (0.01)	0.78 (0.00)
Household income			
High income	0.90 (0.00)	0.78 (0.01)	0.91 (0.00)
Middle income	0.85 (0.00)	0.70 (0.01)	0.87 (0.00)
Low income	0.76 (0.00)	0.57 (0.01)	0.79 (0.00)
<b>Comorbidities</b>			
Arthritis	0.75 (0.00)	0.57 (0.01)	0.77 (0.00)
Cancer	0.78 (0.00)	0.60 (0.01)	0.80 (0.00)
COPD	0.56 (0.01)	0.44 (0.01)	0.60 (0.01)
Diabetes	0.70 (0.00)	0.53 (0.01)	0.72 (0.00)
Hypertension	0.78 (0.00)	0.61 (0.01)	0.80 (0.00)
Kidney failure	0.58 (0.01)	0.45 (0.01)	0.63 (0.01)
Obesity	0.80 (0.00)	0.62 (0.01)	0.82 (0.00)
Abbreviations: ASCVD – atherosclerotic cardiovascular disease. COPD – chronic obstructive pulmonary disease. GED – general educational development.			



**Population**

**$\beta$  (95% CI)**

**$P_{\text{Interaction}}^{\dagger}$**

**Overall<sup>1</sup>**

-0.10 (-0.10, -0.09)

**Sex<sup>2</sup>**

<0.001<sup>‡</sup>

Male

-0.08 (-0.09, -0.07)

Female

-0.11 (-0.12, -0.10)

**Age group<sup>3</sup>**

0.041

18-64 years

-0.09 (-0.10, -0.08)

≥ 65 years

-0.06 (-0.07, -0.06)

**Race/Ethnicity<sup>4\*</sup>**

<0.001<sup>‡</sup>

Non-Hispanic White

-0.09 (-0.10, -0.08)

Non-Hispanic Black


-0.13 (-0.15, -0.11)

Non-Hispanic Asian

-0.09 (-0.13, -0.05)

Hispanic

-0.10 (-0.12, -0.08)



medRxiv preprint doi: <https://doi.org/10.1101/2022.08.31.22279420>; this version posted September 1, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).